

Table 9.25
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2005-2011

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
Lymphoid Neoplasm	171,838	69.0 (68.7 , 69.3)		89.5 (88.8 , 90.2)		76.6 (76.2 , 76.9)		58.4 (57.9 , 59.0)	
1 Hodgkin Lymphoma	14,979	85.9 (85.2 , 86.6)		97.0 (96.1 , 97.8)		89.9 (89.1 , 90.5)		53.6 (50.5 , 56.5)	
1(a) Classical Hodgkin lymphoma	14,215	85.4 (84.7 , 86.1)		96.8 (95.8 , 97.6)		89.6 (88.8 , 90.3)		52.2 (49.2 , 55.2)	
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	2,359	81.0 (79.0 , 82.9)		97.6 (94.0 , 99.0)		87.2 (85.1 , 89.0)		54.4 (48.4 , 60.0)	
1(a)1.1 Lymphocyte-rich	488	88.9 (84.6 , 92.0)		100.0 (- , -)		92.8 (88.3 , 95.6)		67.2 (52.4 , 78.4)	
1(a)1.2 Mixed cellularity	1,684	80.9 (78.5 , 83.1)		96.5 (91.5 , 98.6)		86.8 (84.3 , 89.0)		54.6 (47.3 , 61.3)	
1(a)1.3 Lymphocyte-depleted	187	59.9 (51.2 , 67.6)		- (- , -)		72.3 (61.4 , 80.5)		31.8 (18.0 , 46.6)	
1(a)2. Nodular sclerosis	8,649	90.3 (89.5 , 91.0)		96.8 (95.6 , 97.7)		92.6 (91.8 , 93.3)		57.1 (52.0 , 61.9)	
1(a)3. Classical Hodgkin lymphoma, NOS ^c	3,207	75.2 (73.3 , 77.0)		96.2 (92.1 , 98.2)		82.3 (80.3 , 84.1)		45.0 (40.0 , 49.9)	
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	764	94.3 (91.2 , 96.3)		100.0 (- , -)		95.1 (91.8 , 97.1)		78.5 (57.6 , 89.9)	
2 Non-Hodgkin lymphoma	152,478	67.8 (67.5 , 68.2)		87.4 (86.5 , 88.2)		74.8 (74.4 , 75.2)		59.2 (58.6 , 59.7)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	85	64.4 (50.1 , 75.6)		- (- , -)		71.4 (55.0 , 82.7)		50.5 (25.1 , 71.3)	
4 Lymphoid neoplasm, NOS ^c	4,296	49.3 (47.3 , 51.2)		85.4 (73.9 , 92.2)		61.8 (59.0 , 64.4)		40.1 (37.4 , 42.8)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.